1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Debilitating	_	_	JJ	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	unexplained	_	_	JJ	_	_	_	_	_
4	provoked	_	_	VBN	_	_	_	_	_
5	localized	_	_	VBN	_	_	_	_	_
6	vulvar	_	_	JJ	_	_	_	_	_
7	pain	_	_	NN	_	_	_	_	_
8	or	_	_	CC	_	_	_	_	_
9	vulvodynia	_	_	NN	_	_	_	_	_
10	affects	_	_	VBZ	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	significant	_	_	JJ	_	_	_	_	_
13	proportion	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	~8	_	_	CD	_	_	_	_	_
16	%	_	_	NN	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	women	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	is	_	_	VBZ	_	_	_	_	_
22	epidemiologically	_	_	RB	_	_	_	_	_
23	linked	_	_	VBN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	history	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	both	_	_	CC	_	_	_	_	_
29	seasonal	_	_	JJ	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	contact	_	_	NN	_	_	_	_	_
32	allergies	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Vulvar	_	_	JJ	_	_	_	_	_
2	biopsies	_	_	NNS	_	_	_	_	_
3	from	_	_	IN	_	_	_	_	_
4	diagnosed	_	_	VBN	_	_	_	_	_
5	patients	_	_	NNS	_	_	_	_	_
6	show	_	_	VBP	_	_	_	_	_
7	increases	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	mast	_	_	NN	_	_	_	_	_
10	cells	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	nerves	_	_	NNS	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	recapitulate	_	_	VB	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	dissect	_	_	VB	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	pathobiology	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	allergy-driven	_	_	JJ	_	_	_	_	_
9	tactile	_	_	JJ	_	_	_	_	_
10	sensitivity	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	inform	_	_	VB	_	_	_	_	_
14	novel	_	_	JJ	_	_	_	_	_
15	therapies	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	we	_	_	PRP	_	_	_	_	_
18	established	_	_	VBD	_	_	_	_	_
19	mouse	_	_	NN	_	_	_	_	_
20	models	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	allergy-driven	_	_	JJ	_	_	_	_	_
23	genital	_	_	JJ	_	_	_	_	_
24	pain	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	shown	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	contact	_	_	NN	_	_	_	_	_
6	hypersensitivity	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	commonly	_	_	RB	_	_	_	_	_
10	used	_	_	VBN	_	_	_	_	_
11	laboratory	_	_	NN	_	_	_	_	_
12	haptens	_	_	VBZ	_	_	_	_	_
13	oxazolone	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	Ox	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	labiar	_	_	JJ	_	_	_	_	_
20	skin	_	_	NN	_	_	_	_	_
21	or	_	_	CC	_	_	_	_	_
22	dinitrofluorobenzene	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	DNFB	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	on	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	labiar	_	_	JJ	_	_	_	_	_
29	skin	_	_	NN	_	_	_	_	_
30	or	_	_	CC	_	_	_	_	_
31	vaginal	_	_	JJ	_	_	_	_	_
32	canal	_	_	NN	_	_	_	_	_
33	induces	_	_	VBZ	_	_	_	_	_
34	persistent	_	_	JJ	_	_	_	_	_
35	tactile	_	_	JJ	_	_	_	_	_
36	genital	_	_	JJ	_	_	_	_	_
37	pain	_	_	NN	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	increased	_	_	VBN	_	_	_	_	_
40	accumulation	_	_	NN	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	mast	_	_	NN	_	_	_	_	_
43	cells	_	_	NNS	_	_	_	_	_
44	in	_	_	IN	_	_	_	_	_
45	the	_	_	DT	_	_	_	_	_
46	labiar	_	_	JJ	_	_	_	_	_
47	tissues	_	_	NNS	_	_	_	_	_
48	of	_	_	IN	_	_	_	_	_
49	outbred	_	_	NN	_	_	_	_	_
50	,	_	_	,	_	_	_	_	_
51	female	_	_	JJ	_	_	_	_	_
52	ND4	_	_	NN	_	_	_	_	_
53	mice	_	_	NNS	_	_	_	_	_
54	well	_	_	RB	_	_	_	_	_
55	beyond	_	_	IN	_	_	_	_	_
56	the	_	_	DT	_	_	_	_	_
57	resolution	_	_	NN	_	_	_	_	_
58	of	_	_	IN	_	_	_	_	_
59	visible	_	_	JJ	_	_	_	_	_
60	inflammation	_	_	NN	_	_	_	_	_
61	.	_	_	.	_	_	_	_	_


1	Chemical	_	_	JJ	_	_	_	_	_
2	depletion	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	labiar	_	_	JJ	_	_	_	_	_
5	mast	_	_	NN	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	reduced	_	_	VBD	_	_	_	_	_
8	Ox-driven	_	_	NNP	_	_	_	_	_
9	painful	_	_	JJ	_	_	_	_	_
10	responses	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	therapeutic	_	_	JJ	_	_	_	_	_
13	topical	_	_	JJ	_	_	_	_	_
14	administration	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	Î”-9-tetrahydrocannabinol	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	THC	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	vaginal	_	_	JJ	_	_	_	_	_
23	canal	_	_	NN	_	_	_	_	_
24	alleviated	_	_	VBN	_	_	_	_	_
25	DNFB-induced	_	_	JJ	_	_	_	_	_
26	pain	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	reduced	_	_	VBN	_	_	_	_	_
29	numbers	_	_	NNS	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	accumulated	_	_	VBN	_	_	_	_	_
32	mast	_	_	NN	_	_	_	_	_
33	cells	_	_	NNS	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	affected	_	_	VBN	_	_	_	_	_
37	tissue	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Here	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	examined	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	potential	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	common	_	_	JJ	_	_	_	_	_
10	household	_	_	NN	_	_	_	_	_
11	chemical	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	2-methyl-4-isothiazolin-3-one/methylisothiazolinone	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	MI	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	induce	_	_	VB	_	_	_	_	_
20	contact	_	_	NN	_	_	_	_	_
21	hypersensitivity	_	_	NN	_	_	_	_	_
22	reactions	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	consequent	_	_	JJ	_	_	_	_	_
25	allergy-driven	_	_	JJ	_	_	_	_	_
26	genital	_	_	JJ	_	_	_	_	_
27	pain	_	_	NN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	ND4	_	_	NN	_	_	_	_	_
30	female	_	_	JJ	_	_	_	_	_
31	outbred	_	_	JJ	_	_	_	_	_
32	mice	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	MI	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	biocide	_	_	NN	_	_	_	_	_
5	preservative	_	_	NN	_	_	_	_	_
6	present	_	_	JJ	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	soaps	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	shampoos	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	vaginal	_	_	JJ	_	_	_	_	_
13	washes	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	household	_	_	NN	_	_	_	_	_
16	cleaners	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	paints	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Recent	_	_	JJ	_	_	_	_	_
2	evidence	_	_	NN	_	_	_	_	_
3	suggests	_	_	VBZ	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	significant	_	_	JJ	_	_	_	_	_
7	portion	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	people	_	_	NNS	_	_	_	_	_
10	exposed	_	_	VBN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	MI	_	_	NNP	_	_	_	_	_
13	developed	_	_	VBD	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	capacity	_	_	NN	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	allergic	_	_	JJ	_	_	_	_	_
19	response	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	showed	_	_	VBD	_	_	_	_	_
22	exacerbated	_	_	VBN	_	_	_	_	_
23	inflammatory	_	_	JJ	_	_	_	_	_
24	responses	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	experienced	_	_	VBD	_	_	_	_	_
28	tissue	_	_	NN	_	_	_	_	_
29	injury	_	_	NN	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	skin	_	_	NN	_	_	_	_	_
33	or	_	_	CC	_	_	_	_	_
34	lungs	_	_	NNS	_	_	_	_	_
35	after	_	_	IN	_	_	_	_	_
36	exposure	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Allergic	_	_	JJ	_	_	_	_	_
2	responses	_	_	NNS	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	MI	_	_	NNP	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	also	_	_	RB	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	linked	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	vulvar	_	_	JJ	_	_	_	_	_
11	dermatitis	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	but	_	_	CC	_	_	_	_	_
14	no	_	_	DT	_	_	_	_	_
15	connections	_	_	NNS	_	_	_	_	_
16	between	_	_	IN	_	_	_	_	_
17	such	_	_	JJ	_	_	_	_	_
18	dermatoses	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	later	_	_	JJR	_	_	_	_	_
22	development	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	vulvar	_	_	JJ	_	_	_	_	_
25	pain	_	_	NN	_	_	_	_	_
26	have	_	_	VBP	_	_	_	_	_
27	been	_	_	VBN	_	_	_	_	_
28	made	_	_	VBN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	published	_	_	VBN	_	_	_	_	_
32	clinical	_	_	JJ	_	_	_	_	_
33	literature	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Reed	_	_	NNP	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	colleagues	_	_	NNS	_	_	_	_	_
6	identified	_	_	VBD	_	_	_	_	_
7	exposures	_	_	NNS	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	household	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	workplace	_	_	NN	_	_	_	_	_
12	chemicals	_	_	NNS	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	possible	_	_	JJ	_	_	_	_	_
16	risk	_	_	NN	_	_	_	_	_
17	factor	_	_	NN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	development	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	vulvodynia	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	previously	_	_	RB	_	_	_	_	_
3	published	_	_	VBN	_	_	_	_	_
4	mouse	_	_	NN	_	_	_	_	_
5	models	_	_	NNS	_	_	_	_	_
6	demonstrated	_	_	VBD	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	biological	_	_	JJ	_	_	_	_	_
9	plausibility	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	epidemiological	_	_	JJ	_	_	_	_	_
13	link	_	_	NN	_	_	_	_	_
14	between	_	_	IN	_	_	_	_	_
15	chemical	_	_	JJ	_	_	_	_	_
16	exposures	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	development	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	genital	_	_	JJ	_	_	_	_	_
22	pain	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	specific	_	_	JJ	_	_	_	_	_
5	link	_	_	NN	_	_	_	_	_
6	between	_	_	IN	_	_	_	_	_
7	vulvodynia	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	known	_	_	VBN	_	_	_	_	_
11	environmental	_	_	JJ	_	_	_	_	_
12	chemical	_	_	NN	_	_	_	_	_
13	does	_	_	VBZ	_	_	_	_	_
14	not	_	_	RB	_	_	_	_	_
15	yet	_	_	RB	_	_	_	_	_
16	exist	_	_	VB	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	suggest	_	_	VBP	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	MI	_	_	NNP	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	plausible	_	_	JJ	_	_	_	_	_
8	candidate	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	environmental	_	_	JJ	_	_	_	_	_
12	irritant/allergen	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	that	_	_	IN	_	_	_	_	_
16	exposure	_	_	NN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	MI	_	_	NNP	_	_	_	_	_
19	might	_	_	MD	_	_	_	_	_
20	drive	_	_	VB	_	_	_	_	_
21	allergy-provoked	_	_	JJ	_	_	_	_	_
22	pain	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Here	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	repeatedly	_	_	RB	_	_	_	_	_
5	applied	_	_	VBD	_	_	_	_	_
6	MI	_	_	NNP	_	_	_	_	_
7	dissolved	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	saline	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	surrogate	_	_	NN	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	water-based	_	_	JJ	_	_	_	_	_
15	cleansers	_	_	NNS	_	_	_	_	_
16	that	_	_	WDT	_	_	_	_	_
17	typically	_	_	RB	_	_	_	_	_
18	contain	_	_	VBP	_	_	_	_	_
19	MI	_	_	NN	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	preservative	_	_	NN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	topically	_	_	RB	_	_	_	_	_
25	within	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	vaginal	_	_	JJ	_	_	_	_	_
28	canals	_	_	NNS	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	mice	_	_	NNS	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	characterized	_	_	VBD	_	_	_	_	_
33	consequent	_	_	JJ	_	_	_	_	_
34	allergic	_	_	JJ	_	_	_	_	_
35	inflammation	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	accumulation	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	mast	_	_	NN	_	_	_	_	_
40	cells	_	_	NNS	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	and	_	_	CC	_	_	_	_	_
43	ano-genital	_	_	JJ	_	_	_	_	_
44	sensitivity	_	_	NN	_	_	_	_	_
45	to	_	_	TO	_	_	_	_	_
46	pressure	_	_	NN	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	assessed	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	effects	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	therapeutic	_	_	JJ	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	preventive	_	_	JJ	_	_	_	_	_
10	administration	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	topical	_	_	JJ	_	_	_	_	_
13	THC	_	_	NN	_	_	_	_	_
14	treatments	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	vaginal	_	_	JJ	_	_	_	_	_
18	canal	_	_	NN	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	mast	_	_	NN	_	_	_	_	_
21	cell	_	_	NN	_	_	_	_	_
22	abundance	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	painful	_	_	JJ	_	_	_	_	_
25	sensitivity	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_

